Introduzca una acción o criptomoneda en el cuadro de búsqueda para obtener un resumen
Amplia Therapeutics Ltd
ATXAmplia Therapeutics Limited, a clinical-stage drug development company, engages in the development of focal adhesion kinase (FAK) inhibitors for cancer and fibrosis in Australia. Its product pipeline comprises Narmafotinib (AMP945), an inhibitor of FAK, which is in phase 2a clinical trial for pancreatic cancer; and treatment of idiopathic pulmonary fibrosis, as well as ovarian cancer, other solid tumors, other fibrotic disease, and scar reduction which is in clinical trial. It also develops AMP886, which is in preclinical trial for treating solid tumors. The company was formerly known as Innate Immunotherapeutics Limited and changed its name to Amplia Therapeutics Limited in September 2018. Amplia Therapeutics Limited was incorporated in 2000 and is based in Melbourne, Australia. Address: 350 Queen Street, Melbourne, VIC, Australia, 3000
Analytics
Precio Objetivo de WallStreet
1.1 AUDRelación P/E
–Rentabilidad por dividendo
–Año en curso
Año anterior
Trimestre actual
Último trimestre
Año en curso
Año anterior
Trimestre actual
Último trimestre
Cifras clave ATX
Análisis de dividendos ATX
Aumento del dividendo durante 5 años
–Crecimiento continuo
–Ratio de pago medio en 5 años
–Tendencia del payout ATX
Valoración de la acción ATX
Finanzas ATX
Realice un seguimiento de las métricas clave de cada acción en un solo lugar y sin complicaciones
Hazte premiumResultados | 2019 | Dinámica |